take platform stori come togeth
earn call event sg
guidanc provid got context patisiran launch
prepar pipelin clinic regulatori pathway
alnylam busi lay foundat first launch patisiran
expect sometim aug spite lower
estim assum patient therapi expect
patisiran start slow build momentum
model sale assum approv aug us eu
approv launch like late expect
addit row submiss sinc global right think
diagnosi biggest gate factor relat launch
speed first coupl year alnylam free genet test program
identifi patient ttr mutat continu
import set launch alnylam current patient
us europ expand access program besid compani
manufactur facil prepar await fda inspect
timelin ttr product rel similar approv expect
juli assum alnylam domin market posit
base case import see continu diagnosi market
penetr long term
ep chang lower ep ep
estim vs previou estim
respect risk price target outperform rate includ
lower expect patisiran sale higher expect competit
pressur signific clinic regulatori failur
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
biotechnolog compani research
develop rnai ribonucl acid interfer base
therapeut lead product includ patisiran revusiran
treatment ttr-mediat disord
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
get broad label cardio subgroup patient porphyria
patisiran get label neuropathi patient fitusiran fail
 close
near-term interest happen tafamid studi
studi attr-act on-going oral therapi tafamidi
cardiomyopathi patient tafamidi ttr stabil approv
us fap avail ex-u fap patient endpoint studi
caus mortal cv-hospit frequenc month clinicaltri gov show
estim complet date feb studi accur
would expect data sometim studi patient
arm activ drug placebo also studi wild type famili
patient gener cautiou trial success believ
hurdl success high know ttr stabil lower ttr less
variou late stage catalyst horizon late includ inclisiran
fitusiran lumasiran besid launch underway focu
compani turn back pipelin readout includ lumasirian
data would assum may abl file inclisiran top-lin
data fitusiran hemophilia data although alnylam get royalti
potenti three program think continu clinic success drive
stock valu due strong abil gener good stream diversifi product
rna platform
platform potenti full effect alnylam could anoth launch
horizon late success thesi remain
platform enter sweet spot develop medicin rapidli pick right
diseas candid gener reason stream catalyst remain
confid success interim givosiran porphyria also think lumasirian
remain underappreci watch close whether sanofi opt
program includ model assum success
peak royalti ad valuat off-set gain
increas multipl program move late stage develop reiter
outperform
platform potenti full effect
japan row approv patisiran
sanofi may opt in- know later
data expect
partner medicin compani
top-lin data
partner sanofi
data expect
compani mention price
